Cantor Fitzgerald Reiterates Hold Rating, $38 PT on Cepheid
In a report published Friday, Cantor Fitzgerald reiterated its Hold rating and $38.00 price target on Cepheid (NASDAQ: CPHD).
Cantor Fitzgerald noted, “CPHD continues to hit on target new product launches with the FDA clearance of the Xpert CT/NG test (announced yesterday after the close) before year-end 2012. The CT/NG test, which was launched in Europe (May 2012) and will begin shipping in January in the U.S., represents the first high-volume testing opportunity for CPHD and a meaningful growth driver medium-term, in our view. We are currently modeling ~$35mm contribution from new product launches in 2013 (including CT/NG, MTB/RIF in the U.S., Vaginitis, etc.) representing ~11% of our 20% top-line growth projection for 2013. With hospital capex spending and sustainable margin execution as our primary concerns near-term, we are maintaining our $38 PT and HOLD rating.”
Cepheid closed on Thursday at $32.70.
Latest Ratings for CPHD
|Jun 2016||Morgan Stanley||Initiates Coverage on||Equal-weight|
|Apr 2016||BTIG Research||Upgrades||Neutral||Buy|
|Feb 2016||Stifel Nicolaus||Maintains||Buy|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.